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Abstract
Ethical and effective data-sharing among countries can be achieved by
considering the interests of all relevant parties: research participants,
researchers and funders. Fears of exploitation, however, both of research
participants and researchers from low- and middle-income countries
(LMIC), can undermine the free flow of data necessary for scientific
advancement.
In this Open Letter, two case studies presented at the 2018 Global Forum
on Bioethics in Research meeting on the Ethics of data sharing and
biobanking in Cape Town, South Africa, function as the focal point for a
reflection on the attributes of an ideal model of good data governance and
how it can help support ethical best practices in biobanking and data
sharing.
Consideration of the case studies as well as the literature indicate three
broad principles that need to be reflected in an ideal data governance
framework: (i) collaboration - both among researchers as well as between
researchers and participants, (ii) fairness – ensuring that all parties in
international collaborations, the data provider, primary data gathering LMIC
researcher and the high income country (HIC) institution/funder are treated
fairly, and (iii) working towards a level playing field – neither collaboration
nor fairness can be effectively achieved with the existing power differential
between HIC and LMIC researchers/institutions; it is therefore necessary to
work towards achieving a more level playing field between partners in
research collaborations.
Promoting good governance of data through fair, efficient and accountable
governance frameworks can help build trust and ensure continued
international data sharing.
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Background
International data sharing is garnering greater attention as it 
is now well-established that obstructing the free flow of data 
is an important factor that can threaten global health and glo-
bal security, in addition to impeding the obvious benefits of 
data sharing in healthcare research. The importance of data 
sharing, the ethical imperative to share data and the crite-
ria required for such data sharing to be ethical have been fre-
quently discussed and well-established (Bull et al., 2015; Pisani 
& AbouZahr, 2010; Singh & Shetty, 2017). The literature shows 
almost unanimous agreement on the need to show respect for the 
data-providing research participants and their communities 
through seeking their informed consent for the use of their 
data, engaging the communities in the work and by ensuring 
adequate protection against any potential harm they may suffer 
as a result of providing data and/or samples (Aitken et al., 2016; 
Parker & Bull, 2015). It is equally necessary to consider the 
benefits and interests of all parties relevant to data provision 
and analysis to ensure ethical data sharing and to incentiv-
ize data sharing (Figure 1). The term data is used here in a 
broad sense, encompassing primary and secondary data as 
well as samples that are ultimately converted to data.
To operationalize these considerations, they need to be incor-
porated into ethically appropriate governance frameworks and 
implemented by ethics review boards and access committees 
through access review procedures and oversight processes to 
determine who can have access to data and samples for what 
purposes.
However, the procedures for review and oversight of data and 
sample access are not sufficiently organized to achieve the 
full benefits of data and sample sharing (Tiffin et al., 2019; van 
Panhuis et al., 2014), particularly concerning international trans-
actions of data and samples. Many attempts are being made to 
implement governance frameworks that are globally applicable, as 
well as safeguard the interests and address the concerns of 
all relevant parties. Such an effective framework needs to be 
fair, efficient, show accountability and, just as importantly, be 
sustainable in the long run (de Vries et al., 2017; Klingstrom 
et al., 2016).
Setting up and managing a biobank or a database effectively 
requires extensive laboratory infrastructure, state-of-the-art 
technology and expertise in the collection, storage and analysis 
of data and samples. Although initial funding for setting up 
a biobank is more easily available, long-term funding for 
maintenance of the biobank and data analysis is much scarcer, 
even in high-income countries (HICs) (Doucet et al., 2017). 
Two solutions have been proposed to deal with this issue of lack 
of infrastructure, technology, expertise and funding for data 
storage and analysis in low- and middle-income country 
(LMIC) settings: a commercialization model where samples 
and data are monetized, and secondly, to transfer samples and 
data to HICs where the capacity and infrastructure to store and 
analyse already exists, whilst ensuring access and benefit to the 
data/sample providers from LMIC (Bubela et al., 2015; Doucet 
et al., 2017; Mulder et al., 2017).
The latter situation of data and sample transfer is what hap-
pens most commonly, though providing access and ben-
efit does not necessarily take place. Although data is targeted 
to be open access, data and sample flow is almost always uni-
directional, from LMICs to HICs (Serwadda et al., 2018). 
Deepening concerns about exploitation, fairness and access 
to benefits from data have ultimately led to severe impedi-
ments to critically important data sharing between coun-
tries (Caulfield et al., 2014; Sedyaningsih et al., 2008). The 
concerns regarding governance of international data shar-
ing revolve around several different aspects of this fear of 
exploitation.
Firstly, LMICs are concerned that the samples and data taken 
from pathogens found in their countries are taken and used with-
out their consent to develop vaccines and medicines that are 
later priced at levels unaffordable to LMIC countries, preventing 
the very people who contributed to the treatment development 
from having access to the treatment (Sedyaningsih et al., 2008). 
This is the issue that Indonesia raised in 2007, stating that the 
Figure 1. Good governance requires consideration of benefits and interests of all parties related to research.
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H5N1 samples sent from Indonesia to the World Health Organi-
sation (WHO) were transferred to commercial pharmaceutical 
manufacturers without Indonesia’s consent; a vaccine subse-
quently developed was not affordable or available to citizens 
of the originating countries such as Indonesia and Thailand 
(Hong, 2018). More recently, there were widely reported inci-
dents of scientists from the countries of origin of viral samples 
being unable to access the samples exported to laboratories in 
developed countries (Telegraph, 2019). These samples, which 
remain linked to the patients’ personal data, were admit-
tedly taken and exported to these countries without con-
sent for research from the patients. There are several other 
incidences of countries refusing permission to share viral 
samples – both during the Ebola epidemic and the Yellow 
Fever epidemic in 2016. (Abramowitz et al., 2018).
A second aspect of these concerns regarding exploitation is 
that researchers and research institutions from LMICs do not 
receive the benefits from their initial work in the form of their 
ability to continue the research, attributions and publications 
(Hajduk et al., 2019). Due to insufficient research infrastruc-
ture (technological and human) in LMICs, institutions and 
researchers in well-resourced countries can analyse and publish 
data much faster, resulting in lack of reward (in the form of 
recognition of their efforts and lack of publications, extend-
ing to lack of career progression) for LMIC scientists who 
bear the initial risk and burden of collecting data/samples. For 
example, in the H5N1 case, other countries published and 
presented data analyses of Indonesian virus samples without 
reasonable notification, permission, opportunities for col-
laboration on further research or attribution to the scientists 
generating and sharing the data/samples (Sedyaningsih et al., 
2008). Furthermore, there is a risk of misinterpretation and 
misuse of data when researchers without any connections to 
or understanding of the data-supplying communities engage 
in data analysis. There is also the concern of potential viola-
tions of privacy and patient re-identification, especially in cases 
where patients’ personal data remain linked to the samples/data 
(Pisani & AbouZahr, 2010; Rani & Buckley, 2012).
The case studies below discuss two situations where interna-
tional data sharing caused concerns. The first case discusses 
practical experience of how these concerns were effectively 
managed and the second discusses the results of a qualitative 
study that investigated the underlying causes behind such 
concerns.
Case study 1: 20 years of ethical challenges in 
setting up and maintaining a twin registry and 
biobank in Sri Lanka
The Sri Lanka Twin Registry was set up in 1997 as the first twin 
register in South Asia, by the Institute for Research and Devel-
opment (IRD), Sri Lanka, with funding from the Wellcome 
Trust. It is still one of the very few large-scale, functional, 
population-based twin registries in a LMIC with 9,570 twin 
pairs and 46 triplets from the Colombo district of Sri Lanka, and 
a separate island-wide volunteer register comprising 7,000 twin 
pairs and 86 triplets. The first wave of research using the regis-
ter was the Colombo Twin and Singleton Study (COTASS) 
in 2005, conducted to estimate prevalence, heritability and 
gene-environmental interplay of a range of psychiatric disorders 
(depression, somatisation, post-traumatic stress disorder, and 
substance abuse), resulting in 18 publications and another 
eight papers from the twin research consortium, the CODAT-
wins Project, which pooled data from 67 worldwide twin 
projects. A follow-up study of the same cohort was completed 
in 2016, examining the prevalence and inter-relationship of 
key cardiovascular/metabolic risk markers and diabetes with 
depression and anxiety. The Sri Lankan Twin Registry 
Biobank was established in 2012 as a major component of the 
second wave data collection of COTASS. The biobank consists 
of 3,483 serum and 3,360 DNA samples of twins and single-
tons and is the first twin bio-specimen biobank in South Asia. 
Two papers have been published using the follow-up data 
and two papers submitted, while more are planned. In 2018, 
the Medical Research Council (MRC), UK, awarded a 
pump-priming grant to set up an infant, child and adolescent 
twin registry for mental health research. Ethical sensitivities 
are similar in all projects, arising from the research focus 
including a vulnerable group (minors, some having mental 
illness), involving proxy consent, potential for complex genetic 
and omics research, sensitive personal data and most of all, 
the complications related to international collaborations.
One of the first hurdles the IRD faced when setting up the 
twin registry was the unfounded accusations of collecting and 
exporting genetic information of Sri Lankan twins (Daily 
Mirror Sri Lanka, 2002). The response from the IRD was to 
engage in extensive awareness-raising and community engage-
ment activities using multiple routes, ranging from regular 
newspaper advertisements, feature articles, radio talks, exhibi-
tions, leisure activities and television programmes to the usual 
small group discussions and focus groups, as well as sensitis-
ing other professional and academic groups. The tri-lingual 
magazine of the IRD, ‘Gaveshana’ (Explorations), mainly 
aimed at school children and undergraduates as well as the 
wider general public, published thematic issues on twin 
research, ethics and governance. Cultural activities engaging 
twins, publication of a newsletter in the local languages called 
‘Twin News’, regularly updated and distributed among the 
members of the twin registry, formed part of the community 
engagement activities. 
The lack of ethical guidelines and a governance framework 
that was fit for purpose was another key issue the IRD faced at 
the time of setting up the twin registry. The response of the IRD 
was to initiate standard-setting, based on a blend of the exist-
ing guidelines and the customs, social and moral norms of the 
Sri Lankan culture. The IRD developed and published research 
ethics guidelines titled ‘Research Ethics from a Developing 
World Perspective’ with the help of many Sri Lankan aca-
demics and researchers as well as input from world-leading 
ethics experts. The IRD engaged in extensive work in 
ethics capacity building under the theme ‘Ethics: A friend of 
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Research’ and carried out many Wellcome-funded ethics 
training courses at both basic and advanced levels, earning a 
reputation that later led to the UNESCO Ethics capacity build-
ing programs being delivered in Sri Lanka collaboratively 
with the IRD (2017).
Due to the lack of infrastructure and technical expertise in Sri 
Lanka, it was suggested that the biological samples from the 
twin biobank should be sent abroad for genetic analysis. The 
IRD team chose to delay the genetic analysis and, although it 
took five years, necessary infrastructure including a genetic labo-
ratory as well as research expertise were developed at the IRD 
with extensive support from the Wellcome Trust and international 
collaborators. The decision to delay the genetic work until the 
infrastructure and expertise were developed and the IRD was 
confident of its ability to effectively manage the multiple 
ethical and technical challenges raised by this work has, in 
retrospect, showed itself to be the correct one, since the IRD 
genetic laboratory is now carrying out extensive work in genetic 
analysis. Even more importantly, the capacity building pro-
grams carried out by the IRD in this sphere help build expertise, 
not only in Sri Lanka, but the entire South Asian region.
Critical reflection
As the twin registry was set up at a time when research 
ethics was at a nascent stage of being codified in Sri Lanka, 
the IRD team faced multiple challenges in ensuring that the 
ethical concerns specific to building a database in an LMIC were 
addressed. As the project progressed, the twin database expanded 
into a biobank, bringing about further challenges related to the 
collection, storage, use and protection of samples. The lack 
of consensus on a broad ethical framework and overarching 
ethical guidance was also a key issue at the time. This was 
complicated by the lack of effective guidance on managing rela-
tionships with influential international research collaborations, 
in a manner that was respectful of cultural sensitivities of the 
research participants/communities, ensured research benefits 
were shared equitably and at the same time ensured the 
generation of maximum utility from the research funds.
The negative media campaign that was framed as a warning 
from medical experts sensationalized cultural sensitivities and 
concerns founded on past misdemeanours by other research-
ers and historical injustices. The IRD recognised that the 
concerns, though unfounded in this situation, were valid 
expressions of the mistrust the community had towards 
unethical researchers and therefore aimed to achieve true 
community engagement through developing mutual respect 
and trust to combat misinformation. The activities car-
ried out helped build understanding and awareness about the 
research and helped the twins and wider society to understand 
that the research team viewed them as participants with an 
important role to play in an activity that would benefit human-
kind. This feeling of mutual respect and camaraderie between 
the research team and the participants was the key factor that 
helped the IRD team overcome negative publicity and carry 
out two waves of research among these twins since 1997. 
Existing ethical guidelines and frameworks were reflected on 
and found to address issues that dominate ethics in a West-
ern context and rarely address real life issues faced by LMIC 
researchers. For example, the case studies usually provided 
are rarely applicable in the developing world context, and the 
mechanisms suggested to address ethical issues are not feasible 
in the extremely resource-constrained situations faced in 
LMICs. It is therefore necessary to initiate home-grown 
mechanisms to deal with these constraints and develop 
ethical guidelines and governance frameworks to support LMIC 
researchers. 
The IRD considers that its international research collabo-
rators for the twin registry and biobank-related projects 
exemplified what research collaborations between the global north 
and south should aim for: being generous in sharing expertise, 
carrying out extensive capacity building efforts, supporting Sri 
Lankan researchers by enabling first authorship of publications 
and, most of all, being respectful of cultural sensitivities. Their 
support enabled research capacity building not only at the IRD 
but in the wider Sri Lankan research community through 
numerous training programs. Within this context, the IRD 
had to seriously consider the request to transfer biologi-
cal samples to the UK for analysis based on the premise that 
it would take time to develop the necessary infrastructure and 
expertise in Sri Lanka. It was necessary to weigh the ben-
efits of faster research output by transferring samples abroad 
against the detrimental impact of Sri Lankan researchers 
being relegated to mere sample gatherers and losing the 
long-term benefits of developing capacity in Sri Lanka.
Case study 2: Rumours and fears endanger 
feasibility of biobanking in Liberia
During the Ebola outbreak, many Liberian patients with infec-
tious diseases other than Ebola saw their healthcare needs 
neglected. Malaria became one such rather neglected disease 
and the Saint Joseph’s Catholic Hospital (SJCH) undertook 
a number of measures to support the development of new 
diagnostic, preventive and elimination tools for malaria, as 
well as to enhance local capacity building in malaria research in 
Liberia. In this context, a study was carried out to investigate 
the feasibility of establishing a SJCH-hosted biorepository 
of blood samples obtained from malaria-exposed individuals 
attending the hospital that aimed: i) to support the develop-
ment of improved cost-efficacious high-sensitive malaria 
diagnostic tools; ii) to support quality assessment of presum-
ably substandard and unregistered rapid diagnostic tests that are 
known to be easily available over-the-counter in Liberia, 
and iii) to provide information on the burden of malaria and 
antimalarial resistance to guide public health interven-
tions. This study was nested within a mixed-methods study 
that aimed to assess the burden of malaria among pregnant 
women attending antenatal care at the SJCH (MESA Malaria, 
2018); the qualitative research component of the study explored 
pregnant women’s, traditional leaders’ and health personnel’s 
perspectives on barriers and opportunities for pregnant women 
to consent to participate in malaria research.
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To inform the design of the study and to plan dissemination at 
community-level, a group of ten traditional leaders received 
training in medical research ethics and were invited to consti-
tute a Community Advisory Board. Qualitative research carried 
out among this group explored the drivers of acceptability to 
engage in research that may involve collection, transport, stor-
age, and use of blood samples, i.e. the factors that could directly 
impact the successful establishment and operation of the 
biobank of blood samples. The study revealed that the 
concerns centred primarily around three themes.
Fear of discrimination and restricted access to healthcare: A 
key factor that can impede consent for biobanking is the wide-
spread fear that samples collected in clinical and research set-
tings may be used to test for stigmatizing diseases such as HIV 
without seeking permission from the sample donor. On the 
other hand, given the difficulties of accessing free-of-charge 
healthcare services, fear that refusal to provide samples 
could restrict their access to healthcare, as well as therapeutic 
misconception, can motivate people to consent to participation 
in biobanking.
Cultural issues related to lack of trust and fear of exploita-
tion: Any activity involving blood is considered to be of a 
sensitive nature in the Liberian culture. Blood sample extrac-
tion in a clinical setting is acceptable to most, whereas the 
same activity in a non-clinical setting would be viewed 
with suspicion. This was exacerbated in some cases by 
exposure to Ebola vaccine trials in Monrovia, leading to the 
belief that samples are collected from trial subjects for illicit 
purposes. The generalised lack of trust in the healthcare and 
research establishment impedes voluntary participation in 
biobanking activities. Closely related to the issue of lack of trust 
in healthcare service providers and researchers, there are wide-
spread concerns that researchers would export the samples 
collected for financial benefit without sharing such benefits 
with the researched communities.
Lack of accountability and good governance: Communities 
are aware that during the Ebola epidemics, there were vari-
ous initiatives to collect samples that were subsequently shipped 
abroad for research or public health purposes (i.e. Ebola 
vaccine trials, Ebola Treatment Centers, Plasmapheresis 
Unit). Communities invited to assent to biobanking in Liberia 
may perceive that the destination and usage of exported sam-
ples cannot be controlled by local research staff and, hence, 
that fair conditions for de-identification and re-identification, 
usage, protection of personal data, storage, retrieval, track-
ing and disposal of samples cannot be guaranteed to 
the study participants.
Critical reflection
Fear of discrimination and of exploitation, exacerbated by 
lack of trust in the healthcare system, is the single factor that 
can undermine effective biobanking efforts in Liberia. To help 
re-establish lost trust and for ethical, fair and successful biobank-
ing, it is necessary to engage participants and communities 
by giving them information, empowering them with greater 
decision-making over the use of their data/samples, setting 
up clear mechanisms for accountability and good governance and 
lastly and most importantly, implementing fair benefit sharing 
plans.
Innovative approaches to improve trust, targeted at both 
individuals and communities, need to be designed and imple-
mented ahead of the creation of biobanks. Clear information 
on risks, benefits and compensation, as well as reassurance that 
there will be no negative implications if consent is withheld, 
should be provided during the consent process to all approached 
individuals to avoid undue inducement to participate. Broad 
consent may be inappropriate in these cases as people may want 
to know the exact intended use of their samples and may want 
reassurance that there will be no negative consequences from 
participation. During this study, it was suggested that imple-
menting a stepped wedge consent system could be used so that 
participants can decide exactly what clinical, public health and 
research use of their data and samples they authorize, as well as 
to what type of communication from the biobank regarding the 
use, export, retrieval and disposal of their samples they expect 
to receive. Given the cost and the administrative difficulties, 
it is not feasible to use a stepped wedge consent system in a 
large research population; therefore, a generalised approach to 
sample and data usage could potentially be based on people’s 
preferences derived from this project. 
Sustainability of a biobank in Liberia could largely depend 
on cost recovery of its running costs. Study participants’ 
narratives indicate that community members may not oppose the 
commercialization of their samples provided a benefit sharing 
plan engaging participants and their communities is implemented. 
However, the feasibility of a pay-per-service system should be 
evaluated considering the adverse impact it may have on the 
perception of trustworthiness. To improve trustworthiness, a 
clear structure for accountability and a benefit sharing plan 
needs to be agreed upon by research, regulatory, hospital staff 
and the affected communities at the initiation of a project. 
In addition to improving communication on research plans 
and proposed activities, all stakeholders need to receive accu-
rate information on accountability, human resources, financial 
and sustainability issues. A transparent attitude and willing-
ness to negotiate benefit sharing may help communities trust in 
biobanking research in Liberia.
Discussion and conclusions
Refusal to share data and samples, however legitimate the con-
cerns, is a dangerous trend as it can place global health at 
risk. In response, global health governance aimed to ‘shift to a 
stance that placed greater emphasis on disease as a key secu-
rity threat’ (Youde, 2019). The initial response adopted of dis-
regarding considerations of sovereignty and emphasizing the 
importance of a collective global response failed to be effec-
tive, as sample and data donor countries were not ‘rewarded for 
their contributions to the global health initiatives’ (Carter, 2010), 
and failed to provide mechanisms that would allow equitable 
distribution of benefits derived from data and sample 
sharing.
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Looking at the case studies discussed above, three broad 
principles that form the basis of an ideal model of good 
governance for sharing samples and data internationally can be 
identified.
1.    Collaboration: The model should recognise that 
collaboration among all researchers is essential for 
ethical, fair and sustainable data and sample sharing. 
Leaving aside ‘parachute research’, which is now increas-
ingly condemned, even beneficence as an underlying 
consideration, though it has positive connotations, fails to 
recognise the contributions from the intended ben-
eficiary, preventing true partnership among interna-
tional colleagues. The H3 Africa initiative, for example, 
recognised this factor when it termed that the capac-
ity building work done was ‘in return’ for providing 
access to African data for secondary analysis, rather than 
as a beneficent measure (H3Africa consortium, 2018).
       In the same vein, research participants in LMICs 
should also be considered collaborative partners in 
the research process, as they bear the most significant 
risks, for example, by placing at risk their privacy 
and right to confidentiality when providing data and 
samples. Respect for participants and their communities 
needs to be displayed through implementing con-
sent measures and adequate protections, and greater 
efforts need to be taken to propagate patient and 
public involvement and engagement measures in LMICs, 
similar to what is being done in the global north.
       Funding agencies such as the Wellcome Trust and the 
MRC, UK, have taken great steps forward in promot-
ing a collaborative approach; they now require collabo-
rations with research institutions in the country where 
the research is carried out as a pre-condition of fund-
ing global health research. This collaborative approach 
is, however, taking time to dwindle down to other 
HIC research institutions, which, in some cases claim 
all rights to intellectual property created through the 
research collaboration, contrary to the word and intent 
of the terms and conditions imposed by the funding 
agency, which specify that ownership of intellectual 
property lies with the institution generating it.
2.    Fairness: Fairness towards all participants is essential 
for long-term collaborations. A governance framework 
should ensure fair sharing of benefits with data and 
sample providers, ensure fairness towards the primary 
data/sample collecting researchers by recognising 
their contributions and equally balance the interests 
of science and the funders of data by ensuring that 
maximum benefit is derived from the data collected. 
Simple measures such as a requirement of at least one 
author from the country where the data is collected, 
and a ‘taxonomy of contributor-ship’ indicating the roles 
of authors could help promote fairness (Allen et al., 
2014).
3.    Work towards a level playing field: Neither fairness nor 
collaboration can be effectively achieved with the sig-
nificant power differential that exists between institu-
tions of the global north and the global south. Many 
guidelines for good practice in collaborations exist; 
however, inequity persists. The degree of the ineq-
uity depends on the ‘experience and empowerment of 
the LMIC researchers, research infrastructure… and 
the amount of funding available’ (Hedt-Gauthier et al., 
2018). For over thirty years (if not more), concerned 
individuals and institutions from both sides of the 
divide have been discussing the need for collaboration 
and capacity building to bridge this gap and over the 
past few years, signs of progress are visible. Funding 
agencies such as the Wellcome Trust and the MRC, 
UK, consider collaborations and capacity building as a 
factor when evaluating a research funding application, 
compelling researchers to engage in such efforts. 
       Human capacity building in LMICs is possibly the most 
important step to be taken to reach a more level play-
ing field. Lack of technical and research expertise in 
LMIC research institutions is often cited as the rea-
son for the need for analysis to be carried out in an 
HIC during an international collaboration. It is time to 
lay this poor excuse to rest, particularly in data 
analysis. The world’s most advanced industries using 
state-of-the-art, high-end technology carry out data 
analysis functions in LMICs: Google, for example, has 
nine offices in the South East Asia region, with over 
2,000 data scientists / analysts working in India alone. 
Other ‘big data’ companies – Microsoft, Amazon, 
Oracle – all run offices in LMICs, having success-
fully harnessed the human capacity in LMICs. The 
capacity for data analysis already exists in LMICs, it 
merely needs to be fine-tuned for health research.
The call for more ethical international data sharing and data 
governance, as well as for equitable global research collabora-
tions, has been strengthening consistently. Serwadda et al. (2018) 
addressed similar concerns, stating that ‘credit, capac-
ity and engagement’ are necessary for ethical data sharing. 
Hedt-Gauthier et al. (2018), along with colleagues in both Africa 
and the Americas, recommended steps that could facilitate equity in 
global health research collaborations, which are also directly 
applicable to promoting greater equity in data governance 
frameworks, including: (i) embedding, where HIC collabo-
rators spend enough time in the LMICs of their research to 
support capacity building, training and mentoring; (ii) reward-
ing commitment to building long term partnerships, capac-
ity building  and ensuring fair research fund sharing with LMIC 
institutions.
Learning from past experience, developing and implementing 
ethical governance frameworks so that the interests of both 
data providers and data users are protected and adopting 
processes and mechanisms that help promote data sharing 
but avoid the ‘pitfalls of colonial science’ (Serwadda et al., 2018) 
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are necessary to build the mutual trust that is critical to 
continued international data and sample sharing.
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Data is the new-age currency in the fiercely market-driven economy of the twenty-first century. Data
analysis using information technology has always been an attractive proposition, but in the modern era of
social media and crowd-sourcing, artificial intelligence is fast replacing the conventional IT algorithms. In
such a rapidly evolving global scenario, this article which uses case studies to bring to the fore, the lack of
an the ethically sound "good governance" framework to guide international research collaborations, is
very timely, relevant and welcome. 
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commodity to be bought and sold then it is tempting to consider that "poor" nations might "sell" the
data of their citizens to the "rich" corporate bodies that are believed to be controlling or directing
the course of research, for personal or organizational gains. How much of an impact does societal
corruption have to play in the issue of data-sharing and how it can be prevented from influencing
how data-sharing is done could be factored into the framework suggested. If not the framework, in
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